Suppr超能文献

遗传性头颈部副神经节瘤的遗传学

Genetics of hereditary head and neck paragangliomas.

作者信息

Boedeker Carsten C, Hensen Erik F, Neumann Hartmut P H, Maier Wolfgang, van Nederveen Francien H, Suárez Carlos, Kunst Henricus P, Rodrigo Juan P, Takes Robert P, Pellitteri Phillip K, Rinaldo Alessandra, Ferlito Alfio

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, Albert-Ludwigs University, Freiburg, Germany.

出版信息

Head Neck. 2014 Jun;36(6):907-16. doi: 10.1002/hed.23436. Epub 2013 Nov 30.

Abstract

BACKGROUND

The purpose of this study was to give an overview on hereditary syndromes associated with head and neck paragangliomas (HNPGs).

METHODS

Our methods were the review and discussion of the pertinent literature.

RESULTS

About one third of all patients with HNPGs are carriers of germline mutations. Hereditary HNPGs have been described in association with mutations of 10 different genes. Mutations of the genes succinate dehydrogenase subunit D (SDHD), succinate dehydrogenase complex assembly factor 2 gene (SDHAF2), succinate dehydrogenase subunit C (SDHC), and succinate dehydrogenase subunit B (SDHB) are the cause of paraganglioma syndromes (PGLs) 1, 2, 3, and 4. Succinate dehydrogenase subunit A (SDHA), von Hippel-Lindau (VHL), and transmembrane protein 127 (TMEM127) gene mutations also harbor the risk for HNPG development. HNPGs in patients with rearranged during transfection (RET), neurofibromatosis type 1 (NF1), and MYC-associated factor X (MAX) gene mutations have been described very infrequently.

CONCLUSION

All patients with HNPGs should be offered a molecular genetic screening. This screening may usually be restricted to mutations of the genes SDHD, SDHB, and SDHC. Certain clinical parameters can help to set up the order in which those genes should be tested.

摘要

背景

本研究旨在概述与头颈部副神经节瘤(HNPGs)相关的遗传性综合征。

方法

我们的方法是对相关文献进行综述和讨论。

结果

所有HNPGs患者中约三分之一是种系突变携带者。遗传性HNPGs已被描述与10种不同基因的突变有关。琥珀酸脱氢酶亚基D(SDHD)、琥珀酸脱氢酶复合体组装因子2基因(SDHAF2)、琥珀酸脱氢酶亚基C(SDHC)和琥珀酸脱氢酶亚基B(SDHB)的突变是副神经节瘤综合征(PGLs)1、2、3和4的病因。琥珀酸脱氢酶亚基A(SDHA)、冯·希佩尔-林道(VHL)和跨膜蛋白127(TMEM127)基因突变也有发生HNPGs的风险。转染重排(RET)、1型神经纤维瘤病(NF1)和MYC相关因子X(MAX)基因突变患者中的HNPGs很少被描述。

结论

所有HNPGs患者都应接受分子遗传学筛查。这种筛查通常可能仅限于SDHD、SDHB和SDHC基因的突变。某些临床参数有助于确定这些基因的检测顺序。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验